Please login to the form below

Not currently logged in
Email:
Password:

ASCO

This page shows the latest ASCO news and features for those working in and with pharma, biotech and healthcare.

More good news, and some bad, for Merck’s Keytruda

More good news, and some bad, for Merck’s Keytruda

The SCLC data were presented at last year’s ASCO meeting, at which Merck suggested that the data was an incentive to start testing Keytruda alongside chemotherapy as a first-line

Latest news

  • Bayer, Orion prep challenge in prostate cancer market Bayer, Orion prep challenge in prostate cancer market

    The two partners released top-line results from the ARAMIS trial of darolutamide last year, but have now presented the data in full at the ASCO Genitourinary (GU) symposium and published ... Pfizer and Astellas have just reported positive results from

  • Merck puts prostate cancer firmly in Keytruda’s sights Merck puts prostate cancer firmly in Keytruda’s sights

    KEYNOTE-365 data reported at the ASCO Genitourinary Cancers Symposium this week showed that in patients with castration-resistant prostate cancer (CRPC)   Keytruda improved the efficacy of Lynparza – a PARP inhibitor ... Merck has competition in this

  • Keytruda combo outshines Opdivo in kidney cancer Keytruda combo outshines Opdivo in kidney cancer

    Full details of both trials will be presented at 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco, which starts tomorrow and runs until Saturday. ... The data compares unfavourably with a 60% ORR released at ASCO last year.

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq plus Avastin to Sutent, which showed  positive effects on PFS at last year’s ASCO meeting.

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Nektar disclosed data from the PIVOT trial of NKTR-214 plus BMS’ PD-1 inhibitor Opdivo (nivolumab) at the ASCO meeting last year, although the two companies were forced to defend

More from news
Approximately 20 fully matching, plus 114 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    This will be based on the KEYNOTE-042 trial, which was presented at ASCO last year, where it looked like another hands-down victory for Merck &Co.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid tumours at the American Society of Clinical Oncology (ASCO) meeting this year that disappointed ... ASCO last year, and a larger, 1,

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    On 1 June it presented data on bb2121 at ASCO which showed the therapy could stop the disease in its tracks in the sickest patients, where all other treatments had failed.

  • No incentive for a cure No incentive for a cure

    The systems we have -. from the ICER Value Assessment Framework to the ASCO Value Framework - are often at odds with each other, and none of them wholly addresses all the attributes

  • Avoiding data pitfalls in clinical research Avoiding data pitfalls in clinical research

    Meeting of the American Society of Clinical Oncology (ASCO). ... The pilot was successful enough to be accepted for presentation at the ASCO’s Annual Meeting, the largest academic cancer conference in the world.

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Artificial Intelligence in Healthcare

    Poster presented at: 2017 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2017; Chicago, IL.

  • How did pharma use Twitter at #ASCO16?

    Each year, ASCO’s Annual Meeting brings together 30, 000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this ... ASCO’s Annual Meeting has led the way in terms of social

  • Ashfield

    Each year, ASCO’s Annual Meeting brings together 30, 000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this

  • ASCO 2015: What you missed in Chicago

    Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30, 000 delegates together to talk about innovations ... Three monoclonal antibodies were presented on the last day

  • Blue Latitude Health

    ASCO 2015: What you missed in Chicago. ... Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30, 000 delegates together to talk about innovations

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics